INSYS Therapeutics Names New General Counsel
October 10, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 10, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East
October 01, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics to Present at 2018 Cantor Global Healthcare Conference
September 27, 2018 18:53 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Completes Initial Clinical Study of Dronabinol Inhalation with Innovative Breath-Actuated Inhaler
September 24, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 24, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics to Present at Janney Healthcare Conference
September 14, 2018 14:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 14, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis
September 04, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis
August 30, 2018 06:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors
August 09, 2018 07:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Reports Second Quarter 2018 Results
August 08, 2018 16:15 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids (CBD) and spray...
INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation
August 08, 2018 07:00 ET
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...